nach oben

Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie

Erschienen in:

01.05.2014 | CME Zertifizierte Fortbildung

Diabetische Retinopathie

Krankheitsbild, Diagnostik und Therapiemöglichkeiten

verfasst von: N. Wahrlich, S. Uibel, D. Klingelhoefer, Prof. Dr. D.A. Groneberg

Erschienen in: Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Diabetes mellitus (DM) ist in Industrienationen die Hauptursache vermeidbarer Blindheit der arbeitenden Bevölkerung. Fünfzehn Jahre nach der Diagnosestellung sind bereits 80 % der Typ-2-Diabetes-Patienten mit sekundärer Insulinbedürftigkeit an diabetischer Retinopathie (DR) erkrankt. Zehn Jahre nach der Diagnosestellung erblinden ca. 4 % der Betroffenen. Eine strenge Blutzuckereinstellung wirkt der Entwicklung der DR entgegen und senkt das Risiko für Visusverluste. Regelmäßige Vorsorgeuntersuchungen und diagnostische Genauigkeit sind unerlässlich, da die DR aufgrund des Ausbleibens der Symptome oft lange unbemerkt bleibt, obwohl sie bereits therapiebedürftig wäre. Durch die rechtzeitige Erkennung und Behandlung kann das Erblindungsrisiko signifikant gesenkt werden. In den letzten 30 Jahren haben Laserkoagulation, frühe chirurgische Interventionen und gezielte Pharmakotherapien das Behandlungsergebnis der DR deutlich verbessert.

Lemmen KD, Martin S (2008) Diabetic retinopathy and maculopathy. Diabetologe 492–92

Bunce C, Wormald R (2006) Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health 6:58PubMedCentralPubMedCrossRef

Fong DS, Aiello L et al (2004) Retinopathy in diabetes. Diabetes Care 27(Suppl 1):S84–S87PubMedCrossRef

Hutchinson A, McIntosh A, Peters J et al (2000) Effectiveness of screening and monitoring tests for diabetic retinopathy – a systematic review. Diabet Med 17:495–506PubMedCrossRef

Klein R, Klein BE, Moss SE (1984) Visual impairment in diabetes. Ophthalmology 91:1–9PubMedCrossRef

Klein R, Klein BE, Moss SE et al (1984) The Wisconsin epidemiologic study of diabetic retinopathy. III Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527–532PubMedCrossRef

Klein R, Klein BE, Moss SE et al (1984) The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520–526PubMedCrossRef

Malone JI, Morrison AD et al (2001) Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years‘ duration screened for the diabetes control and complications trial. Diabetes Care 24:522–526PubMedCrossRef

Williams R, Airey M et al (2004) Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 18:963–983PubMedCrossRef

10.

Bertram B, Wolf S et al (1991) Retinal blood-flow in diabetic children and adolescents. Graefes Arch Clin Exp Ophthalmol 229:336–340PubMedCrossRef

11.

Klein R, Klein BE, Moss SE, Cruickshanks KJ (1995) The Wisconsin epidemiologic-study of diabetic-retinopathy.XV. The long-term incidence of macular edema. Ophthalmology 102:7–16PubMedCrossRef

12.

Turner RC, Holman RR et al (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef

13.

Hammes HP, Bertram B, Bornfeld N et al (2004) Diagnostik, Therapie und Verlaufskontrolle der diabetischen Retinopathie und Makulopathie. Evidenzbasierte Leitlinie der Deutschen Diabetes-Gesellschaft (DDG). http://www.deutsche-diabetes-gesellschaft.de/leitlinien/EBL_Retinopathie_Update_2004.pdf. Zugegriffen: 20. Feb. 2009

14.

Singh R, Ramasamy K et al (2008) Diabetic retinopathy: an update. Indian J Ophthalmol 56:179–188PubMedCentralCrossRef

15.

Moss SE, Klein R et al (1993) 10 year incidence of visual loss in a diabetic population. ARVO Annual Meeting, Sarasota, Fl. Lippincott-Raven, Philadelphia

16.

Lemmen KD, Bornfeld N (2008) Pathophysiology and classification of diabetic retinopathy and maculopathy. Diabetologe 49:3–

17.

Robison WG Jr, Nagata M et al (1989) Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Vis Sci 30:2285–2292PubMed

18.

Speiser P, Gittelsohn AM, Patz A (1968) Studies on diabetic retinopathy. 3. Influence of diabetes on intramural pericytes. Arch Ophthalmol 80:332–337PubMedCrossRef

19.

Koya D, King GL (1998) Protein kinase C activation and the development of diabetic complications. Diabetes 47:859–866PubMedCrossRef

20.

Kohner EM, Patel V et al (1995) Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 44:603–607PubMedCrossRef

21.

Early Treatment Diabetic Retinopathy Study Research Group (1991) Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98(5 Suppl):766–785CrossRef

22.

Machemer R, MD., Duke Univ. Medical School, Durham, NC, USA. Diabetische Retinopathie, nichtproliferativ. Online J Ophthalmology http://www.atlasophthalmology.com/atlas/folder.jsf?node=1989&locale=de

23.

Machemer R, M.D., Duke Univ. Medical School, Durham, NC, USA. Diabetische Retinopathie, proliferativ. Online Journal of Ophthalmology. http://www.atlasophthalmology.com/atlas/folder.jsf?node=1988&locale=de

24.

McCuen B, MD, Duke University Eye Center, Durham, NC, USA. Diabetische Retinopathie, proliferativ. Online Journal of Ophtalmology. http://www.atlasophthalmology.com/atlas/folder.jsf?node=1988&locale=de

25.

Shamoon H, Duffy H et al (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef

26.

Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol 116:874–886CrossRef

27.

UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317:703–713CrossRef

28.

UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 317:713–720CrossRef

29.

Mathiesen ER, Rønn B, Storm B et al (1995) The natural course of microalbuminuria in insulin-dependent diabetes – a 10-year prospective study. Diabet Med 12:482–487PubMedCrossRef

30.

Leslie RD, Pyke DA (1982) Diabetic retinopathy in identical twins. Diabetes 31:19–21PubMedCrossRef

31.

Wong TY, Klein R et al (2006) Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 141:446–455PubMedCentralPubMedCrossRef

32.

Diabetes Control and Complications Trial Research Group (1997) Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 46:1829–1839CrossRef

33.

Liew G, Klein R et al (2009) The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin 49:35–52PubMedCentralPubMedCrossRef

34.

Malek M, Khamseh ME et al (2012) Medical management of diabetic retinopathy: an overview. Arch Iran Med 15:635–640PubMed

35.

Chew EY, Klein ML, Ferris FL 3rd et al (1996) Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 114:1079–1084PubMedCrossRef

36.

Gupta A, Gupta V et al (2004) Lipid-lowering drug atorvastastin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 137:675–682PubMed

37.

Toth PP, Simko RJ et al (2012) The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 11:109PubMedCentralPubMedCrossRef

38.

Wu M, Lyons TJ (2011) Treatment approaches for diabetes and dyslipidemia. Horm Res Paediatr 76(Suppl 1):76–80PubMedCentralPubMedCrossRef

39.

Keech A, Simes RJ et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500):1849–1861PubMedCrossRef

40.

Davis MD, Fisher MR, Gangnon RE et al (1998) Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 39:233–252PubMed

41.

Singh R, Gupta V et al (2005) Spontaneous closure of microaneurysms in diabetic retinopathy with treatment of coexisting anaemia. Br J Ophthalmol 89:248–249PubMedCentralPubMedCrossRef

42.

Costa F, Soares R (2009) Nicotine: a pro-angiogenic factor. Life Sci 84:785–790PubMedCrossRef

43.

Chase HP, Garg SK et al (1991) Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 265:614–617PubMedCrossRef

44.

Chaturvedi N, Stephenson JM et al (1995) The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study. Diabetes Care 18:785–792PubMedCrossRef

45.

Muhlhauser I, Bender R et al (1996) Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabet Med 13:536–543PubMedCrossRef

46.

Klein R, Klein BE, Jensen SC, Moss SE (1994) The relation of socioeconomic factors to the incidence of proliferative diabetic retinopathy and loss of vision. Ophthalmology 101:68–76PubMedCrossRef

47.

Horvat M, Maclean H et al (1980) Diabetic retinopathy in pregnancy – a 12-year prospective study. Br J Ophthalmol 64:398–403PubMedCentralPubMedCrossRef

48.

Moloney JB, Drury MI (1982) The effect of pregnancy on the natural course of diabetic retinopathy. Am J Ophthalmol 93:745–756PubMed

49.

Bertram B (1998) Diabetikerbetreuung in deutschen Augenarztpraxen. Augenarzt: 289–291

50.

Klein R, Meuer SM et al (1995) Retinal microaneurysm counts and 10-year progression of diabetic retinopathy. Arch Ophthalmol 113:1386–1391PubMedCrossRef

51.

Kollias AN, Ulbig MW (2010) Diabetic retinopathy: early diagnosis and effective treatment. Dtsch Arztebl Int 107:75–83PubMedCentralPubMed

52.

Danne T, Kordonouri O et al (1998) Monitoring for retinopathy in children and adolescents with type 1 diabetes. Acta Paediatr Suppl 425:35–41PubMed

53.

Klein R, Klein BE, Moss SE(1989) The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab Rev 5:559–570PubMedCrossRef

54.

Klein BE, Klein R, Meuer SM et al (1988) Does the severity of diabetic retinopathy predict pregnancy outcome? J Diabet Complications 2:179–184PubMedCrossRef

55.

Klein BE, Moss SE, Klein R (1990) Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 13:34–40PubMedCrossRef

56.

Lin DY, Blumenkranz MS et al (2002) The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. Am J Ophthalmol 134:204–213PubMedCrossRef

57.

Williams GA, Scott IU et al (2004) Single-field fundus photography for diabetic retinopathy screening – a report by the American Academy of Ophthalmology. Ophthalmology 111:1055–1062PubMedCrossRef

58.

Early Treatment Diabetic Retinopathy Study Research Group (1991) ETDRS report no 13: fluorescein angiographic risk factors for progression of diabetic retinopathy. Ophthalmology 98(5 Suppl):834–840CrossRef

59.

Mardin C (o J) Proliferative diabetische Retinopathie (PDR) #2, Angiogramm. Erlangen, University Erlangen-Nürnberg, http://www.atlasophthalmology.com/atlas/photo.jsf;jsessionid=11A57AF5F85AB06DB05E6B49ACE78096?node=6806&locale=de. Zugegriffen: 15. Dez. 2008

60.

Schneeberg AE, Göbel W (2003) Diagnostik und Verlaufskontrolle des nichtdiabetischen Makulaödems mithilfe der optischen Kohärenztomographie. Ophthalmologe 100:960–966PubMedCrossRef

61.

Elsing S, Durham N (2009) Diabetische Retinopathie, proliferativ, OCT. http://www.atlasophthalmology.com/atlas/photo.jsf?node=3352&locale=de. Zugegriffen: 10. Jan. 2009

62.

Bressler SB (1993) Does wavelength matter when photocoagulating eyes with macular degeneration or diabetic retinopathy? Arch Ophthalmol 111:177–180PubMedCrossRef

63.

Diabetic Retinopathy Study Research Group (1976) Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 81:383–396

64.

Diabetic Retinopathy Study Research Group (1981) Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 88:583–600CrossRef

65.

Early Treatment Diabetic Retinopathy Study Research Group (1987) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology 94:761–774CrossRef

66.

Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103:1796–1806CrossRef

67.

Kylstra JA, Brown JC et al (1999) The importance of fluorescein angiography in planning laser treatment of diabetic macular edema. Ophthalmology 106:2068–2073PubMedCrossRef

68.

Diabetic Retinopathy Vitrectomy Study (1990) Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 108:958–964CrossRef

69.

Nauck M, Roth M et al (1997) Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 16:398–406PubMedCrossRef

70.

Jonas JB, Degenring R (2002) Intravitreal injection of crystalline triamcinolone acetonide in the treatment of diffuse diabetic macular oedema. Klin Monbl Augenheilkd 219:429–432PubMedCrossRef

71.

Martidis A, Duker JS et al (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927PubMedCrossRef

72.

Aiello LP, Avery RL et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMedCrossRef

73.

Karim R, Tang B (2010) Use of antivascular endothelial growth factor for diabetic macular edema. Clin Ophthalmol 25:493–517CrossRef

74.

Chun DW, Heier JS, Topping TM et al (2006) A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113:1706–1712PubMedCrossRef

75.

Cunningham ET, Adamis AP et al (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Annual Meeting of the Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL. Elsevier, Amsterdam

76.

Haritoglou C, Kook D et al (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999–1005PubMedCrossRef

77.

Nguyen QD, Tatlipinar S et al (2006) Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142:961–969PubMedCrossRef

78.

Mason JO, Nixon PA et al (2006) Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 142:685–688PubMedCrossRef

79.

Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278PubMedCrossRef

80.

Xia P, Aiello LP et al (1996) Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98:2018–2026PubMedCentralPubMedCrossRef

81.

Aiello LP, Clermont A et al (2006) Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 47:86–92PubMedCrossRef

82.

PKC-DRS Study Group (2005) The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy initial – results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54:2188–2197CrossRef

83.

Strom C, Sander B et al (2005) Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci 46:3855–3858PubMedCrossRef

84.

Boehm BO, Lang GK et al (2001) Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 33:300–306PubMedCrossRef

85.

Grant MB, Mames RN et al (2000) The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy – a randomized controlled study. Diabetes Care 23:504–509PubMedCrossRef

86.

Sennlaub F, Valamanesh F et al (2003) Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 108:198–204PubMedCrossRef

87.

Gilbert RE, Kelly DJ et al (2000) Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 43:1360–1367PubMedCrossRef

88.

Jackson WE, Holmes DL et al (1992) Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy. Ann Ophthalmol 24:99–103PubMed

89.

Knudsen ST, Bek T et al (2003) Effects of losartan on diabetic maculopathy in type 2 diabetic patients: a randomized, double-masked study. J Intern Med 254:147–158PubMedCrossRef

90.

Rachmani R, Lidar M et al (2000) Effect of enalapril on the incidence of retinopathy in normotensive patients with type 2 diabetes. Eur J Intern Med 11:48–50CrossRef

91.

Pradhan R, Fong D, March C et al (2002) Angiotensin-converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive type 2 diabetic patients. A pilot study. J Diabetes Complications 16:377–381PubMedCrossRef

92.

VISION-2020 (2007) Maßnahmen – Blindheitsverhütung in Deutschland.“ Vision 2020. http://vision2020deutschland.de/massnahmen/verh_deutsch.php. Zugegriffen: 07. Juni 2010

93.

Bierwirth RA, Grimm C et al (2008) The cost of diabetic retinopathy and nephropathy in Germany. Diabetologe 4: ###

94.

DGUV (Hrsg) (2010) Leitfaden für Betriebsärzte zur Anwendung des G 25. http://publikationen.dguv.de/dguv/pdf/10002/g25.pdf. Zugegriffen: 06. Jan. 2013

Titel: Diabetische Retinopathie
Krankheitsbild, Diagnostik und Therapiemöglichkeiten
verfasst von: N. Wahrlich
S. Uibel
D. Klingelhoefer
Prof. Dr. D.A. Groneberg
Publikationsdatum: 01.05.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie / Ausgabe 3/2014
Print ISSN: 0944-2502
Elektronische ISSN: 2198-0713
DOI: https://doi.org/10.1007/s40664-013-0003-3

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Diabetische Retinopathie

Krankheitsbild, Diagnostik und Therapiemöglichkeiten

Zusammenfassung

Leitlinien kompakt für die Allgemeinmedizin

Facharzt-Training Allgemeinmedizin

Neu im Fachgebiet Allgemeinmedizin

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Ärztliche Empathie hilft gegen Rückenschmerzen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Update Allgemeinmedizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

DWS-Richtwertestudie

Kardiomyopathie durch Kobaltintoxikation

Eichenprozessionsspinner

Kälteprovokationstests nach DIN ISO 14835-1

Priv.-Doz. Dr.-Ing. Matthias Jäger, Mitglied der Schriftleitung, 60 Jahre

Gefahren durch polychlorierte Biphenyle – eine Schule vor der Sanierung

Leitlinien kompakt für die Allgemeinmedizin

Facharzt-Training Allgemeinmedizin

Neu im Fachgebiet Allgemeinmedizin

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Ärztliche Empathie hilft gegen Rückenschmerzen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Update Allgemeinmedizin